Emergent Biosolutions Inc. Stock
Emergent Biosolutions Inc. shows a slight decrease today, losing -€0.032 (-0.350%) compared to yesterday.
Emergent Biosolutions Inc. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 13 € there is a positive potential of 43.9% for Emergent Biosolutions Inc. compared to the current price of 9.03 €.
Our community identified positive and negative aspects for Emergent Biosolutions Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Emergent Biosolutions Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc. | -0.350% | -2.630% | -4.705% | 13.236% | -13.051% | -40.659% | -90.687% |
| Iovance Biotherapeutics Inc. | 1.470% | 5.787% | 13.888% | -56.434% | -2.508% | -66.329% | -93.975% |
| United Therapeutics | 1.460% | 1.597% | 1.622% | 14.222% | -4.704% | 70.163% | 188.794% |
| Neurocrine Bioscience | -0.050% | -6.865% | -5.478% | -1.146% | -11.635% | 11.415% | 14.954% |
Comments
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat